FDA Requests Teleconference to Discuss Repros Therapeutics Inc. Phase 2 Protocol for Proellex® in the Treatment of Endometriosis Last Week of August

THE WOODLANDS, Texas, July 30, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has scheduled a meeting to discuss the design of a Phase 2 endometriosis protocol for low dose oral Proellex®. The teleconference will be held during the last week of August 2012. The Company has submitted the Phase 2 protocol for FDA review. The Company looks forward to the Agency's advice.